EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility

Benjamin G Hale iD

European Journal of Immunology · 2023-06 · 53 (6)

DOI: 10.1002/eji.202250164 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Immunology, online erschienen am 06.06.2023. Verfasst von Benjamin G Hale. Beteiligte Einrichtung: Institute of Medical Virology, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland. Hauptthemen laut MEDLINE: Interferon Type I, COVID-19, Virus Diseases. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The type I IFN (IFN‐I) system is essential to limit severe viral disease in humans. Thus, IFN‐I deficiencies are associated with serious life‐threatening infections. Remarkably, some rare individuals with chronic autoimmune diseases develop neutralizing autoantibodies (autoAbs) against IFN‐Is thereby compromising their own innate antiviral defenses. Furthermore, the prevalence of anti‐IFN‐I autoAbs in apparently healthy individuals increases with age, such that ∼4% of those over 70 years old are affected. Here, I review the literature on factors that may predispose individuals to develop anti‐IFN‐I autoAbs, such as reduced self‐tolerance caused by defects in the genes AIRE , NFKB2 , and FOXP3 (among others), or by generally impaired thymus function, including thymic involution in the elderly. In addition, I discuss the hypothesis that predisposed individuals develop anti‐IFN‐I autoAbs following “autoimmunization” with IFN‐Is generated during some acute viral infections, systemic inflammatory events, or chronic IFN‐I exposure. Finally, I highlight the enhanced susceptibility that individuals with anti‐IFN‐I autoAbs appear to have towards viral diseases such as severe COVID‐19, influenza, or herpes (e.g., varicella‐zoster virus, herpes simplex virus, cytomegalovirus), as well as adverse reactions to live‐attenuated vaccines. Understanding the mechanisms underlying development and consequences of anti‐IFN‐I autoAbs will be key to implementing effective prophylactic and therapeutic measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Type ICOVID-19Virus DiseasesHumansAgedAutoantibodiesPrevalenceDisease SusceptibilityInterferons

Stichwörter der Autor:innen

autoantibodiesautoimmunityinterferonself-toleranceviral disease

Substanzen

AutoantibodiesInterferon Type IInterferons

Autor:innen und Institutionen

  • Institute of Medical Virology, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.

ORCID-Profile: Benjamin G Hale

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Hale, B. G. (2023). Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility. European Journal of Immunology, 53(6). https://doi.org/10.1002/eji.202250164

Vancouver

Hale BG. Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility. European Journal of Immunology. 2023;53(6). doi:10.1002/eji.202250164

BibTeX
@article{Hale2023,
  author = {Hale, Benjamin G},
  title = {Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility},
  journal = {European Journal of Immunology},
  year = {2023},
  volume = {53},
  number = {6},
  doi = {10.1002/eji.202250164}
}
Kostenlos starten →